BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $100 at Credit Suisse

October 28, 2021 5:49 AM

Credit Suisse analyst Martin Auster lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $100.00 (from $102.00) while maintaining a Outperform rating.

No results found